Coronary Artery Diseases Clinical Trial
— SEEDSOfficial title:
Clinical Trial Program of a Medical Instrument Product
This is a prospective, multi-center registry to evaluate safety and effectiveness of the Everolimus Drug Eluting Stent for treatment coronary revascularization in Chinese patients with long lesion, small vessel or multi-vessel diseases.
Status | Recruiting |
Enrollment | 1900 |
Est. completion date | June 2013 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. The patient must be =18 of age; male or (non-pregnant and non-breast feeding) female. 2. Diagnosis of stable angina, unstable angina or silent ischemia (evidence of myocardial ischemia). 3. Target lesion is at least length = 25mm (visual estimate); or the number of target lesion is = 2; or target vessel diameter = 2.75mm. 4. At least one target lesion with a diameter stenosis =70% (visual estimate) 5. Acceptable candidate for CABG; 6. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided written Notice of Informed Consent, appropriate Ethics Committee(EC); and the patient is willing to comply with specified follow-up evaluations. Exclusion Criteria: 1. Patients have evidence of an Acute Myocardial Infarction within a week prior to the index procedure. 2. Patient has congenital heart disease, severe valve dysfunction, bridge vascular disease, severe heart failure (NYHA = ? level), or left ventricular ejection fraction = 30%. 3. Patient has undergone previous stenting anywhere within the previous 1 year. 4. Patient has a preoperative renal dysfunction: serum creatinine> 2.0mg/dl (176.82umol / L). 5. Patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated or in which patient will not be able to comply with dual antiplatelet therapy for at least 1 year; 6. Patient has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, Prasugrel, stainless steel alloy, cobalt chromium, rapamycin, styrene-butylene-styrene or poly-lactic acid (PLA) polymer, and/or contrast sensitivity that cannot be adequately premedicated; Patient is allergic to contrast agent Sirolimus. 7. Patient has other medical illness (e.g., cancer, known malignancy , congestive heart failure, organ transplant recipient or candidate) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy is less than 12 months. 8. Currently participating in another investigational drug or device study or patient in inclusion in another investigational drug or device study during follow-up 9. Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study; Patient has poor compliance with the judgment of the investigator and can not complete the study as required. 10. Patient who had heart transplant. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Fuwai Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
CCRF Consulting Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | TVF | Ischemia-driven Target Vessel Failure (TVF) which is a composite of cardiac death, myocardial infarction (Q and non-Q wave) and target vessel revascularization (TVR),12 months post-index procedure. | 12 months post-index procedure. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00328315 -
Cardiac SPECT With Rotating Slant Hole Collimator
|
||
Recruiting |
NCT02257710 -
BIOFLOW-III UK Satellite Registry Orsiro Stent System
|
N/A | |
Active, not recruiting |
NCT02273648 -
BIOTRONIK - BIOFLOW-III Registry French Satellite
|
N/A | |
Completed |
NCT02028728 -
BIOFLOW III Satellite-Italy Orsiro Stent System
|
N/A | |
Completed |
NCT02813473 -
SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease
|
||
Completed |
NCT05853250 -
Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery
|
N/A | |
Recruiting |
NCT02635230 -
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
|
||
Completed |
NCT01116882 -
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
|
N/A | |
Completed |
NCT00920283 -
COMPETE: A Clinical Evaluation of Chrono Carbostent Carbofilm™ Coated Stent
|
N/A | |
Completed |
NCT01700075 -
Physical and Chemical Study of Atherosclerosis Mechanisms
|
Phase 4 | |
Completed |
NCT00607217 -
The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases
|
Phase 2/Phase 3 | |
Completed |
NCT00607178 -
The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05486780 -
The Effect of Digital Window on Day and Night Perception Status and Sleep Quality in Intensive Care Patients
|
N/A | |
Terminated |
NCT01665248 -
Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina
|
N/A | |
Terminated |
NCT01612819 -
DXR Stent(Previous Cilotax) Implantation Registry
|
N/A | |
Active, not recruiting |
NCT01226355 -
NOYA CoCr Biodegradable Coating Sirolimus-Eluting Coronary Stent System
|
N/A | |
Recruiting |
NCT02247492 -
BIOFLOW-III VIP Russia Registry Orsiro Stent System
|